Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
EMBO Rep ; 24(3): e55536, 2023 03 06.
Article in English | MEDLINE | ID: mdl-36705069

ABSTRACT

The cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) axis is the predominant DNA sensing system in cells of the innate immune system. However, human T cells also express high levels of STING, while its role and physiological trigger remain largely unknown. Here, we show that the cGAS-STING pathway is indeed functional in human primary T cells. In the presence of a TCR-engaging signal, both cGAS and STING activation switches T cells into type I interferon-producing cells. However, T cell function is severely compromised following STING activation, as evidenced by increased cell death, decreased proliferation, and impaired metabolism. Interestingly, these different phenotypes bifurcate at the level of STING. While antiviral immunity and cell death require the transcription factor interferon regulatory factor 3 (IRF3), decreased proliferation is mediated by STING independently of IRF3. In summary, we demonstrate that human T cells possess a functional cGAS-STING signaling pathway that can contribute to antiviral immunity. However, regardless of its potential antiviral role, the activation of the cGAS-STING pathway negatively affects T cell function at multiple levels. Taken together, these results could help inform the future development of cGAS-STING-targeted immunotherapies.


Subject(s)
Interferon Type I , Nucleotidyltransferases , Humans , Nucleotidyltransferases/metabolism , Signal Transduction , Antiviral Agents , T-Lymphocytes , Immunity, Innate
2.
Blood ; 140(10): 1104-1118, 2022 09 08.
Article in English | MEDLINE | ID: mdl-35878001

ABSTRACT

T-cell-recruiting bispecific molecule therapy has yielded promising results in patients with hematologic malignancies; however, resistance and subsequent relapse remains a major challenge. T-cell exhaustion induced by persistent antigen stimulation or tonic receptor signaling has been reported to compromise outcomes of T-cell-based immunotherapies. The impact of continuous exposure to bispecifics on T-cell function, however, remains poorly understood. In relapsed/refractory B-cell precursor acute lymphoblastic leukemia patients, 28-day continuous infusion with the CD19xCD3 bispecific molecule blinatumomab led to declining T-cell function. In an in vitro model system, mimicking 28-day continuous infusion with the half-life-extended CD19xCD3 bispecific AMG 562, we identified hallmark features of exhaustion arising over time. Continuous AMG 562 exposure induced progressive loss of T-cell function (day 7 vs day 28 mean specific lysis: 88.4% vs 8.6%; n = 6; P = .0003). Treatment-free intervals (TFIs), achieved by AMG 562 withdrawal, were identified as a powerful strategy for counteracting exhaustion. TFIs induced strong functional reinvigoration of T cells (continuous vs TFI-specific lysis on day 14: 34.9% vs 93.4%; n = 6; P < .0001) and transcriptional reprogramming. Furthermore, use of a TFI led to improved T-cell expansion and tumor control in vivo. Our data demonstrate the relevance of T-cell exhaustion in bispecific antibody therapy and highlight that T cells can be functionally and transcriptionally rejuvenated with TFIs. In view of the growing number of bispecific molecules being evaluated in clinical trials, our findings emphasize the need to consider and evaluate TFIs in application schedules to improve clinical outcomes.


Subject(s)
Antibodies, Bispecific , Antineoplastic Agents , Lymphoma, B-Cell , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Antibodies, Bispecific/pharmacology , Antibodies, Bispecific/therapeutic use , Antigens, CD19 , Antineoplastic Agents/therapeutic use , Humans , Immunotherapy/methods , Lymphoma, B-Cell/drug therapy , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , T-Lymphocytes
3.
Cancer Immunol Immunother ; 72(7): 2499-2512, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37041225

ABSTRACT

Bispecific T-cell engager (BiTE®) molecules recruit T cells to cancer cells through CD3ε binding, independently of T-cell receptor (TCR) specificity. Whereas physiological T-cell activation is dependent on signal 1 (TCR engagement) and signal 2 (co-stimulation), BiTE molecule-mediated T-cell activation occurs without additional co-stimulation. As co-stimulatory and inhibitory molecules modulate the strength and nature of T-cell responses, we studied the impact of the expression profile of those molecules on target cells for BiTE molecule-mediated T-cell activation in the context of acute myeloid leukemia (AML). Accordingly, we created a novel in vitro model system using murine Ba/F3 cells transduced with human CD33 ± CD86 ± PD-L1. T-cell fitness was assessed by T-cell function assays in co-cultures and immune synapse formation by applying a CD33 BiTE molecule (AMG 330). Using our cell-based model platform, we found that the expression of positive co-stimulatory molecules on target cells markedly enhanced BiTE molecule-mediated T-cell activation. The initiation and stability of the immune synapse between T cells and target cells were significantly increased through the expression of CD86 on target cells. By contrast, the co-inhibitory molecule PD-L1 impaired the stability of BiTE molecule-induced immune synapses and subsequent T-cell responses. We validated our findings in primary T-cell-AML co-cultures, demonstrating a PD-L1-mediated reduction in redirected T-cell activation. The addition of the immunomodulatory drug (IMiD) lenalidomide to co-cultures led to stabilization of immune synapses and improved subsequent T-cell responses. We conclude that target cells modulate CD33 BiTE molecule-dependent T-cell activation and hence, combinatorial strategies might contribute to enhanced efficacy.


Subject(s)
Antibodies, Bispecific , Leukemia, Myeloid, Acute , Animals , Humans , Mice , B7-H1 Antigen/metabolism , Immune Checkpoint Proteins/metabolism , Receptors, Antigen, T-Cell/metabolism , Sialic Acid Binding Ig-like Lectin 3/metabolism , T-Lymphocytes
6.
Fogorv Sz ; 98(3): 109-11, 2005 Jun.
Article in Hungarian | MEDLINE | ID: mdl-16108414

ABSTRACT

On the basis of the information gained from the literature the amoxicillin/clavulanic acid combination has attained the leading position in dentistry and outpatient oral surgery practices as regards the order of application of antibiotics. The explanation for this may be that in 60-70% of the cases of odontogenic inflammation, besides the pathogenic anaerobic bacteria there is an increasing necessity to eliminate beta-lactamase-producing bacteria as well. The authors applied the amoxicillin/clavulanic acid combination (Aktil Duo 625 mg) to support the--primarily surgical--treatment of 14 oral and dental surgery conditions on a total of 60 patients. After analysing the results and side effects they came to the conclusion that the application of the mentioned combination was very successful in dentistry and outpatient oral surgery practices.


Subject(s)
Ambulatory Care , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis/methods , Dentistry, Operative , Drug Therapy, Combination/therapeutic use , beta-Lactamase Inhibitors , Adolescent , Adult , Aged , Ambulatory Care/methods , Amoxicillin-Potassium Clavulanate Combination/administration & dosage , Anti-Bacterial Agents/administration & dosage , Dentistry, Operative/methods , Drug Administration Schedule , Drug Therapy, Combination/administration & dosage , Enzyme Inhibitors/therapeutic use , Female , Humans , Male , Middle Aged , Outpatients , Retrospective Studies , Surgery, Oral , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL